Advertisement
New Zealand markets closed
  • NZX 50

    11,811.81
    -134.62 (-1.13%)
     
  • NZD/USD

    0.5958
    +0.0009 (+0.14%)
     
  • NZD/EUR

    0.5555
    +0.0014 (+0.26%)
     
  • ALL ORDS

    7,844.80
    -92.70 (-1.17%)
     
  • ASX 200

    7,583.50
    -99.50 (-1.30%)
     
  • OIL

    83.84
    +0.27 (+0.32%)
     
  • GOLD

    2,347.20
    +4.70 (+0.20%)
     
  • NASDAQ

    17,430.50
    -96.30 (-0.55%)
     
  • FTSE

    8,078.86
    +38.48 (+0.48%)
     
  • Dow Jones

    38,085.80
    -375.12 (-0.98%)
     
  • DAX

    17,917.28
    -171.42 (-0.95%)
     
  • Hang Seng

    17,626.75
    +342.21 (+1.98%)
     
  • NIKKEI 225

    38,032.13
    +403.65 (+1.07%)
     
  • NZD/JPY

    93.0090
    +0.5130 (+0.55%)
     

Analysts’ Recommendations for Johnson & Johnson on April 16

Analysts’ Recommendations for Johnson & Johnson on April 16

Johnson & Johnson (JNJ) reported revenues of $20.2 billion during 4Q17—11.5% growth compared to 4Q16. Wall Street analysts expect Johnson & Johnson to generate earnings per share of $2.00 on revenues of $19.4 billion in 1Q18—9.2% revenue growth compared to $17.8 billion in 1Q17. The revenue growth is expected to be driven by increased sales across all three business segments.